About this video
The DolPHIN 2 Clinical Trial is designed to yield high-quality evidence on the efficacy and safety of dolutegravir in late presenting pregnant women, to allow definitive recommendations for use of dolutegravir to reduce MTCT in this high-risk scenario.
The study commenced recruitment in January 2018 and recruited over 268 late presenting HIV+ pregnant women who were randomised 1:1 to DTG- or EFV-containing cART. The trial primary outcome analysis was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2019.
Women living with HIV starting dolutegravir (DTG)-based ART after presenting in late pregnancy achieved more rapid virological suppression before delivery than those who started with an efavirenz (EFV)-based regimen.